Initial Request Statement Review
The National Institute on Aging (NIA) will review based on the following evaluation criteria:
- Appropriateness: ADNI samples are not for use in technology development.
- Significance for advancing our understanding of AD and related dementias.
- Scientific quality of the proposal.
- Duplication of existing or approved studies and data already available from ADNI.
- Commitment to data sharing as specified by ADNI. [Data Use Agreement]
- Ability for investigator(s) to carry out the proposed work.
- Impact on ADNI inventory of samples.
The NIA reviews Initial Request Statements and aims to provide a response within approximately one week. Approved requestors will be invited to submit the appropriate ADNI Full Application.
Invitation to Submit Full Application
Submit the Appropriate Full Application
To make the most of the rich and complex ADNI data and biosamples available, please review the documents on the right before submitting a Full Application.
Depending on the sample type in your approved Initial Request Statement, please provide all information requested in the appropriate ADNI Biospecimens Full Application:
Full Application submission timing
All RARCs will use the calendar below for their review cycles.
Date
Submitted |
Approximate
Date of
Review |
| 7/1 -8/31 | 10/1 |
| 9/1-10/31 | 12/1 |
| 11/1-12/31 | 2/1 |
| 1/1-2/28 | 4/1 |
| 3/1-4/30 | 6/1 |
| 5/1- 6/30 | 8/1 |
Full Application Review & Decision
Full Application Review & Decision
Applications will be reviewed by the appropriate RARC, which will provide its recommendation to the National Institute on Aging (NIA). The RARC reviews applications based on several criteria:
- Appropriateness: ADNI samples are not to be used for technology development
- Significance for advancing our understanding of AD and related dementias.
- Scientific quality of the proposal.
- Duplication of existing studies and data already available from ADNI
- Commitment to data sharing as specified by ADNI [Data Use Agreement]
- Ability for investigator(s) to carry out the proposed work.
- Impact on ADNI inventory of samples.
Applicant receives a decision
Within 2-3 weeks of the review, the NIA will notify the applicant of the review decision via email. The NIA may provide reviewer comments to the investigator, but will not provide a summary statement. Resubmissions will not be considered unless invited by the RARC or approved by the NIA. There is no appeal process.
Complexity of ADNI Samples and RARCs
Biosample Policies
Full Application submission timing
All RARCs will use the calendar below for their review cycles.
Date
Submitted |
Approximate
Date of
Review |
| 7/1 -8/31 | 10/1 |
| 9/1-10/31 | 12/1 |
| 11/1-12/31 | 2/1 |
| 1/1-2/28 | 4/1 |
| 3/1-4/30 | 6/1 |
| 5/1- 6/30 | 8/1 |
Samples Released & Quarterly Updates
Samples distribution is discussed and samples shipped
The NIA will notify the ADNI Biomarker/Genetics/Neuropathology Core when a RARC Full Application is approved. The Core will work with approved investigators to finalize details about sample transfer. See Biosample Policies on RARC for MTA information. See NCRAD Pricing Schedule for costs of genetic sample distribution. While we do not charge for samples, there are associated costs for aliquoting, shipping, etc. which the investigator must cover.
Samples will be shipped to the receiving investigator in a blinded fashion. The samples will be unblinded after the investigator submits study results back to the Core. Unblinded results are released to all ADNI data users on LONI, there is no embargo of results.
Biosample Policies on RARC
NCRAD Pricing Structure
Applicant must report a quarterly update on study progress
Each quarter that passes after an investigator has received samples, the requesting investigator must send a quarterly update on their study’s progress to catherine.conti@ucsf.edu.
In their Full Application, the investigator provides a timeline for expected results to come back to ADNI. If the originally proposed timeline is expected to be delayed more than a few weeks, the investigator must notify ADNI immediately. However, we strongly recommend that all investigators keep within their proposed timeline.
If an investigator’s ability to provide the data is substantially delayed, ADNI reserves the right to request that the samples be returned ASAP.
Applicant must report residual samples and additional studies
The investigator should notify NIA if there are residual samples left after completion of the RARC-approved study. Investigators are required to receive NIA approval (and RARC concurrence) before using residual samples in a new study. Investigators should not dispose of unused ADNI biofluid. Investigators may return residual samples to the Biomarker Core, where they will be pooled and used for assay standardization. Residual brain tissue is not to be used for additional unapproved studies.
